1. <a href="/resources/view/natural-history-beta-cell-dysfunction-niddm">Leahy JL. Natural history of beta-cell dysfunction in NIDDM. Diabetes Care1990;13:992-1010.</a>
2. <a href="/resources/view/glycemic-durability-rosiglitazone-metformin-or-glyburide-monotherapy">Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G, for the ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443.</a>
3. <a href="/resources/view/clinical-review-135-importance-beta-cell-failure-development-and-progression-type-2-0">Kahn SE. The importance of ß-Cell failure in the development and progression of type 2 diabetes. J. Clin. Endocrinol. Metab 2001; 86: 4047-4058.</a>
4. <a href="/resources/view/banting-lecture-triumvirate-ominous-octet-new-paradigm-treatment-type-2-diabetes-mell">DeFronzo RA. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773-795.</a>
5. <a href="/resources/view/intensive-blood-glucose-control-sulphonylureas-or-insulin-compared-conventional-treat">UKPDS Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.</a>
6. <a href="/resources/view/epidemiologic-relationships-between-a1c-and-all-cause-mortality-during-median-34-year">Riddle MC, Ambrosius WT, Brillon DJ, Buse JB, Byington RB, Cohen RM, Goff, Jr. DC, Malozowski S, Margolis KL, Probstfield JL, Schnall A, Seaquist ER, and for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 201;33:983-990.</a>
7. <a href="/resources/view/contributions-fasting-and-postprandial-plasma-glucose-increments-overall-diurnal-hype">Monnier L, Lapinski Hand Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c.Diabetes Care 2003;26:881-885.</a>
8. <a href="/resources/view/effect-thiazolidinedione-drug-troglitazone-glycemia-patients-type-2-diabetes-mellitus">Yale JF, Valiquett TR, Ghazzi MN, Owens-Grillo JK, Whitcomb RW, Foyt HL, and for the Troglitazone Triple-Therapy Study Group. The effect of a thiazolidinedione drug, troglitazone, on glycemia in patients with type 2 diabetes mellitus poorly controlled with sulfonylurea and metformin: a multicenter, randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;134:737-745.</a>
9. <a href="/resources/view/efficacy-and-safety-sitagliptin-when-added-ongoing-metformin-therapy-patients-type-2-">Scott R, Loeys T, Davies MJ, Engel SS, for the Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008;10:959-969.</a>
10. <a href="/resources/view/efficacy-and-safety-saxagliptin-when-added-metformin-therapy-patients-inadequately-co">DeFronzo RA, Hissa MN, Garber AJ, Gross JL, Duan RY, Ravichandran S, Chen RS, and for the Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009 ;32:1649-1655.</a>
11. Package insert for sitagliptin and saxagliptin, September 2010.
12. <a href="/resources/view/medical-management-hyperglycemia-type-2-diabetes-consensus-algorithm-initiation-and-a">Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009;32:193–203.</a>
13. <a href="/resources/view/statement-american-association-clinical-endocrinologistsamerican-college-endocrinolog">Rodbard HW, Jellinger PS, Davidson JA, Einhorn D, Garber AJ, Grunberger G, Handelman Y, Horton ES, Lebovitz H, Levy P, Moghissi E, and Schwartz SS. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009;15:540-559.</a>
14. <a href="/resources/view/liraglutide-once-day-versus-exenatide-twice-day-type-2-diabetes-26-week-randomised-pa">Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L. LEAD-6 Study Group. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39– 47.</a>
15. <a href="/resources/view/incretin-based-therapies-treatment-type-2-diabetes-evaluation-risks-and-benefits">Drucker DJ, Sherman SI, Gorelick FS, Bergenstal RM, Sherwin RS, and Buse JB. Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 2010;33:428-433.</a>
16. <a href="/resources/view/treat-target-trial-randomized-addition-glargine-or-human-nph-insulin-oral-therapy-typ">Riddle MC, Rosenstock J, and Gerich J. The. Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-3086.</a>
17. <a href="/resources/view/26-week-randomized-parallel-treat-target-trial-comparing-insulin-detemir-nph-insulin-">Hermansen K, Davies M, Derezinski T, Ravn GM, Clauson P, and Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir With NPH insulin as add_on therapy to oral glucose-lowering drugs in insulin-naive people With type 2 diabetes. Diabetes Care 2006;291269-1274.</a>
18. <a href="/resources/view/randomized-trial-adding-insulin-glargine-vs-avoidance-insulin-people-type-2-diabetes-">Gerstein HC, Yale JF, Harris SB, Issa M, Stewart JA, Dempsey E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23:736-742.</a>
19. <a href="/resources/view/three-year-efficacy-complex-insulin-regimens-type-2-diabetes">Holman RR, Farmer AJ, Davies MJ, Levy JC, Darbyshire JL, M.A., Keenan JF, B.A., and Paul SK, for the 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361:1736-1747.</a>
20. <a href="/resources/view/once-daily-insulin-detemir-comparable-once-daily-insulin-glargine-providing-glycaemic">King, AB. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. Diabetes, Obesity and Metabolism 2009;11:69–71.</a>
21. Shaefer, CF. Unpublished data. Cost Analysis of 90 day diabetes therapy. June 2010.
22. Hirsch, IB. Oral communication. ADA 68th Scientific Sessions, Chicago, IL, 2007.
Disclosure:
Charles Shaefer has received honoraria as a speaker for Sanofi-Aventis, Novo Nordisk, Amylin, Eli Lilly, Bristol Myers Squibb, AstraZeneca, Novartis, Abbott Labs, Forest Pharmaceuticals, Daiichi Sankyo, and Pfizer. He has acted as a consultant for Sanofi-Aventis, Amylin, and Eli Lilly.